TY - JOUR
T1 - Possible implications of MCAM expression in metastasis and non-metastatic of primary uveal melanoma patients
AU - Beutel, Julia
AU - Wegner, Jürgen
AU - Wegner, Rayime
AU - Ziemssen, Focke
AU - Nassar, Khaled
AU - Rohrbach, Jens Martin
AU - Hilgers, Ralf Dieter
AU - Lüke, Matthias
AU - Grisanti, Salvatore
PY - 2009/11/1
Y1 - 2009/11/1
N2 - Purpose: To evaluate the expression of melanoma cell adhesion molecule (MCAM) as prognostic factor in uveal melanoma patients. Methods: Paraffin sections from 35 primary uveal melanomas were analyzed immunhistochemically for the expression of MCAM. Further known prognostic factors such as cell type, ciliary body invasion, tumor stage, and local extension were evaluated. In 16 cases, patients had developed metastatic disease. The patients without metastasis (n19) had a mean follow-up of 10.6 (913) years. Results: All tumors were positive for MCAM (mean: 57.05%). In the group without metastasis, an average MCAM expression of 35.37% (SD 19.66%) compared to 82.78% (SD 11.73%) in the metastasis group was found. The Cox regression analysis showed a significant association of an enhanced MCAM expression and death due to metastasis (HR: 365.48, 95% CI: 18.51, 7217.85). Conclusion: MCAM expression of primary uveal melanomas can serve as a possible prognostic parameter for metastasis. If further experiments approve the cellular adhesion molecules to account for early micrometastasis of tumor cells, a possible target might be available for future treatment.
AB - Purpose: To evaluate the expression of melanoma cell adhesion molecule (MCAM) as prognostic factor in uveal melanoma patients. Methods: Paraffin sections from 35 primary uveal melanomas were analyzed immunhistochemically for the expression of MCAM. Further known prognostic factors such as cell type, ciliary body invasion, tumor stage, and local extension were evaluated. In 16 cases, patients had developed metastatic disease. The patients without metastasis (n19) had a mean follow-up of 10.6 (913) years. Results: All tumors were positive for MCAM (mean: 57.05%). In the group without metastasis, an average MCAM expression of 35.37% (SD 19.66%) compared to 82.78% (SD 11.73%) in the metastasis group was found. The Cox regression analysis showed a significant association of an enhanced MCAM expression and death due to metastasis (HR: 365.48, 95% CI: 18.51, 7217.85). Conclusion: MCAM expression of primary uveal melanomas can serve as a possible prognostic parameter for metastasis. If further experiments approve the cellular adhesion molecules to account for early micrometastasis of tumor cells, a possible target might be available for future treatment.
UR - http://www.scopus.com/inward/record.url?scp=72449136322&partnerID=8YFLogxK
U2 - 10.3109/02713680903262205
DO - 10.3109/02713680903262205
M3 - Journal articles
C2 - 19958117
AN - SCOPUS:72449136322
SN - 0271-3683
VL - 34
SP - 1004
EP - 1009
JO - Current Eye Research
JF - Current Eye Research
IS - 11
ER -